Literature DB >> 18809569

Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability.

Laura L Pontano1, Priya Aggarwal, Olena Barbash, Eric J Brown, Craig H Bassing, J Alan Diehl.   

Abstract

While mitogenic induction of cyclin D1 contributes to cell cycle progression, ubiquitin-mediated proteolysis buffers this accumulation and prevents aberrant proliferation. Because the failure to degrade cyclin D1 during S-phase triggers DNA rereplication, we have investigated cellular regulation of cyclin D1 following genotoxic stress. These data reveal that expression of cyclin D1 alleles refractory to phosphorylation- and ubiquitin-mediated degradation increase the frequency of chromatid breaks following DNA damage. Double-strand break-dependent cyclin D1 degradation requires ATM and GSK3beta, which in turn mediate cyclin D1 phosphorylation. Phosphorylated cyclin D1 is targeted for proteasomal degradation after ubiquitylation by SCF(Fbx4-alphaBcrystallin). Loss of Fbx4-dependent degradation triggers radio-resistant DNA synthesis, thereby sensitizing cells to S-phase-specific chemotherapeutic intervention. These data suggest that failure to degrade cyclin D1 compromises the intra-S-phase checkpoint and suggest that cyclin D1 degradation is a vital cellular response necessary to prevent genomic instability following genotoxic insult.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809569      PMCID: PMC2593367          DOI: 10.1128/MCB.01085-08

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  47 in total

Review 1.  Checking on DNA damage in S phase.

Authors:  Jiri Bartek; Claudia Lukas; Jiri Lukas
Journal:  Nat Rev Mol Cell Biol       Date:  2004-10       Impact factor: 94.444

Review 2.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

3.  Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis.

Authors:  V Bianchi; E Pontis; P Reichard
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

4.  Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage.

Authors:  Jian Hu; Chad M McCall; Tomohiko Ohta; Yue Xiong
Journal:  Nat Cell Biol       Date:  2004-09-26       Impact factor: 28.824

5.  Cyclin D1 protein expression and function in human breast cancer.

Authors:  J Bartkova; J Lukas; H Müller; D Lützhøft; M Strauss; J Bartek
Journal:  Int J Cancer       Date:  1994-05-01       Impact factor: 7.396

6.  The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas.

Authors:  J Bartkova; J Lukas; M Strauss; J Bartek
Journal:  Int J Cancer       Date:  1994-08-15       Impact factor: 7.396

7.  Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer.

Authors:  J Bartkova; J Lukas; H Müller; M Strauss; B Gusterson; J Bartek
Journal:  Cancer Res       Date:  1995-02-15       Impact factor: 12.701

8.  Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle.

Authors:  H Matsushime; M F Roussel; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

9.  Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein.

Authors:  M Hatakeyama; J A Brill; G R Fink; R A Weinberg
Journal:  Genes Dev       Date:  1994-08-01       Impact factor: 11.361

10.  Comparison of checkpoint responses triggered by DNA polymerase inhibition versus DNA damaging agents.

Authors:  Jen-Sing Liu; Shu-Ru Kuo; Thomas Melendy
Journal:  Mutat Res       Date:  2003-11-27       Impact factor: 2.433

View more
  36 in total

Review 1.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

Review 2.  The role of aberrant proteolysis in lymphomagenesis.

Authors:  Anagh A Sahasrabuddhe; Kojo S J Elenitoba-Johnson
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

3.  Cyclin D3: To translate or not to translate.

Authors:  J Alan Diehl
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

4.  C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression.

Authors:  Snehalata A Pawar; Tapasree Roy Sarkar; Kuppusamy Balamurugan; Shikha Sharan; Jun Wang; Youhong Zhang; Steven F Dowdy; A-Mei Huang; Esta Sterneck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

5.  Hst3 is turned over by a replication stress-responsive SCF(Cdc4) phospho-degron.

Authors:  Ellen R Edenberg; Ajay A Vashisht; Benjamin R Topacio; James A Wohlschlegel; David P Toczyski
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-08       Impact factor: 11.205

Review 6.  Cyclin D degradation by E3 ligases in cancer progression and treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  Semin Cancer Biol       Date:  2020-01-30       Impact factor: 15.707

7.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 8.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

9.  ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis.

Authors:  L P Vaites; Z Lian; E K Lee; B Yin; A DeMicco; C H Bassing; J A Diehl
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

10.  Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF(Fbx4/alphaB-crystallin) ligase and subsequent proteasome-dependent degradation.

Authors:  O Barbash; E Egan; L L Pontano; J Kosak; J A Diehl
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.